Aurinia Announces Public Offering of Common Shares
December 09 2019 - 6:01AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia”
or the “Company”), a late-stage clinical biopharmaceutical company
focused on advancing voclosporin in multiple indications, today
announced that it has commenced a registered underwritten public
offering of US$150,000,000 of its common shares (the
“Offering”).
Jefferies LLC and SVB Leerink LLC are acting as joint
book-running managers for the Offering. H.C. Wainwright & Co.
LLC, Oppenheimer & Co. Inc., and Bloom Burton Securities Inc.
are acting as co-managers for the Offering.
The Company will grant the underwriters an option exercisable,
in whole or in part, in the sole discretion of the underwriters, to
purchase up to an aggregate of US$22,500,000 of additional shares,
for a period of up to 30 days. The Offering is subject to market
conditions, and there can be no assurance as to whether or when the
Offering may be completed, or as to the actual size or terms of the
Offering.
The Company intends to use the net proceeds of the Offering for
pre-commercialization and launch activities, as well as working
capital and general corporate purposes.
The Offering is subject to customary closing conditions,
including NASDAQ and TSX approvals. For the purposes of the TSX
approval, the Company intends to rely on the exemption set forth in
Section 602.1 of the TSX Company Manual, which provides that the
TSX will not apply its standards to certain transactions involving
eligible interlisted issuers on a recognized exchange, such as
NASDAQ.
The Offering is being made pursuant to a U.S. registration
statement on Form F-10, declared effective by the United States
Securities and Exchange Commission (the “SEC”) on March 29, 2018
(the “Registration Statement”), and the Company’s existing Canadian
short form base shelf prospectus (the “Base Shelf Prospectus”)
dated March 26, 2018. The prospectus supplements relating to the
Offering (together with the Base Shelf Prospectus and the
Registration Statement, the “Offering Documents”) will be filed
with the securities commissions in the provinces of British
Columbia, Alberta and Ontario in Canada, and with the SEC in the
United States. The Offering Documents will contain important
detailed information about the securities being offered. Before you
invest, you should read the Offering Documents and the other
documents the Company has filed for more complete information about
the Company and the Offering. Copies of the Offering Documents will
be available for free by visiting the Company’s profiles on the
SEDAR website maintained by the Canadian Securities Administrators
at www.sedar.com or the SEC’s website at www.sec.gov, as
applicable. Alternatively, copies of the prospectus supplement will
be available upon request by contacting Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022; by phone at (877) 821-7388; or by e-mail
at Prospectus_Department@Jefferies.com; or SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by
email at syndicate@svbleerink.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, nor will there be any
sale of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
ABOUT AURINIA
Aurinia Pharmaceuticals is a late-clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are impacted
by serious diseases with a high unmet medical need. The Company is
currently developing an investigational drug, for the treatment of
lupus nephritis, focal segmental glomerulosclerosis and dry eye
syndrome. The Company’s head office is in Victoria, British
Columbia and focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191209005255/en/
Investors & Media: Glenn Schulman, PharmD, MPH SVP,
Corporate Communications & IR gschulman@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024